Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Veralox submits IND to the FDA for VLX-1005

Jan. 13, 2021

Promising data presented from global phase III study with valoctocogene roxaparvovec in hemophilia A

Jan. 12, 2021

Forma begins phase II/III study of FT-4202 in sickle cell disease

Jan. 12, 2021

Imara reports phase IIa data on IMR-687 in sickle cell disease

Jan. 7, 2021

Novel thrombosis mouse models using Jak2 platelet conditional knockout

Jan. 4, 2021

Transgenic mice allow study of erythroferrone overexpression

Dec. 29, 2020

Geron initiates phase III study of imetelstat in myelofibrosis refractory to JAK inhibitors

Dec. 28, 2020

Enrollment ongoing in phase II study of PHA-022121

Dec. 28, 2020

DISC-A demonstrates efficacy in low hepcidin rat model

Dec. 28, 2020

DISC-0974 decreases hepcidin and increases transferrin saturation in inflammation models

Dec. 28, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 7, 2024.
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...
Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity
BioWorld
After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.